We are live on ! Find out more
NVS icon

Novartis

937 hedge funds and large institutions have $22.2B invested in Novartis in 2017 Q3 according to their latest regulatory filings, with 70 funds opening new positions, 348 increasing their positions, 336 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more call options, than puts

Call options by funds: $41.3M | Put options by funds: $22.2M

59% more first-time investments, than exits

New positions opened: 70 | Existing positions closed: 44

2% more funds holding

Funds holding: 920937 (+17)

4% more repeat investments, than reductions

Existing positions increased: 348 | Existing positions reduced: 336

2% more capital invested

Capital invested by funds: $21.7B → $22.2B (+$474M)

0.06% less ownership

Funds ownership: 11.09%11.03% (-0.06%)

5% less funds holding in top 10

Funds holding in top 10: 4038 (-2)

Holders
937
Holders Change
+17
Holders Change %
+1.85%
% of All Funds
23.36%
Holding in Top 10
38
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-5%
% of All Funds
0.95%
New
70
Increased
348
Reduced
336
Closed
44
Calls
$41.3M
Puts
$22.2M
Net Calls
+$19.2M
Net Calls Change
-$5M
Name Holding Trade Value Shares
Change
Change in
Stake
ACM
151
Advisors Capital Management
New Jersey
$11.3M -$93.4K -1,237 -0.8%
Connor, Clark & Lunn Investment Management (CC&L)
152
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$11.3M +$11.1M +146,615 New
CSIC
153
Clifford Swan Investment Counsel
California
$11.1M +$284K +3,761 +3%
PSC
154
Prentiss Smith & Co
Vermont
$10.8M -$221K -2,926 -2%
FT
155
Fiduciary Trust
Massachusetts
$10.5M -$303K -4,018 -3%
NPF
156
Norris Perne & French
Michigan
$10.4M +$199K +2,629 +2%
D.E. Shaw & Co
157
D.E. Shaw & Co
New York
$10.1M +$9.96M +131,929 New
WIC
158
Wilkins Investment Counsel
Massachusetts
$10.1M +$8.46K +112 +0.1%
RJFSA
159
Raymond James Financial Services Advisors
Florida
$10M +$2.12K +28 +0%
CT
160
Cambridge Trust
Massachusetts
$9.98M +$779K +10,320 +9%
GD
161
Grandfield & Dodd
New York
$9.72M +$1.31M +17,382 +16%
GJIC
162
Gamble Jones Investment Counsel
California
$9.67M -$195K -2,585 -2%
TNB
163
Thomasville National Bank
Georgia
$9.62M +$145K +1,921 +2%
TAM
164
Trillium Asset Management
Massachusetts
$9.59M +$580K +7,684 +7%
TCOV
165
Trust Company of Vermont
Vermont
$9.54M +$35.3K +467 +0.4%
WF
166
Welch & Forbes
Massachusetts
$9.4M +$175K +2,316 +2%
AAM
167
Advisors Asset Management
Colorado
$9.35M -$456K -6,036 -5%
VW
168
Vantage Wealth
California
$9.12M -$26.6K -352 -0.3%
VV
169
Verity & Verity
South Carolina
$9.11M +$72.1K +955 +0.8%
PA
170
Pinnacle Associates
New York
$9.04M +$348K +4,607 +4%
FNBOO
171
First National Bank of Omaha
Nebraska
$8.56M +$374K +4,956 +5%
GC
172
Gratus Capital
Georgia
$8.55M +$207K +2,743 +3%
TBA
173
Tower Bridge Advisors
Pennsylvania
$8.49M +$623K +8,255 +8%
GCC
174
Guardian Capital (Canada)
Ontario, Canada
$8.42M +$1.08M +14,321 +15%
AAIM
175
American Assets Investment Management
California
$8.41M

NVS Hedge Fund Activity: Q3 2017 in Review

937 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2017, worth a combined $22.2B — up 2.2% from $21.7B a quarter earlier.

Buyers outnumbered sellers: 70 funds opened new NVS positions and 44 closed out — a net gain of 26 holders — while 348 added to existing stakes and 336 trimmed.

The largest buyer was Bank of America, adding an estimated $158M. The largest seller was Dodge & Cox, cutting an estimated $464M.

  • 937 institutional investors held Novartis (NVS) as of Q3 2017, up from 920 in Q2 2017.
  • Funds reported $22.2B of Novartis stock for Q3 2017, up 2.2% quarter-over-quarter.
  • 70 funds opened new Novartis positions in Q3 2017 and 44 closed out, a net change of +26 holders.
  • The largest Novartis buyer in Q3 2017 was Bank of America, an estimated $158M added.
  • The largest Novartis seller in Q3 2017 was Dodge & Cox, an estimated $464M sold.

Based on aggregated 13F filings for Q3 2017.